Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda Pharmaceutical Co. Currently has a Zacks ... the components of the Momentum Style Score for TAK that show why this company shows promise as a solid momentum pick. Looking at a stock's ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Takedas dengue vaccine Qdenga is set to launch in India by 2026 through a partnership with Biological E offering hope against rising dengue cases with local production and global backing ...